Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × abemaciclib × 90 days × Clear all

Phase

Status

Recruiting 29 Active not recruiting 23 Completed 5 Not yet recruiting 3 Withdrawn 1 Terminated 1 Suspended 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 5 Cyclophosphamide 4 fludarabine 3 Paclitaxel 3 fludarabine phosphate 2 decitabine and cedazuridine drug combination 2 aldesleukin 2 Magnetic Resonance Spectroscopy 2 Granulocyte Colony-Stimulating Factor 2 Filgrastim 2 Biopsy 2 zimberelimab 1 venetoclax 1 vedolizumab 1 tremelimumab 1 trastuzumab deruxtecan 1 tazemetostat 1 ribociclib 1 regorafenib 1 peginterferon alfa-2a 1 olaparib 1 lenvatinib 1 inavolisib 1 gallium 68 PSMA-11 1 enfortumab vedotin 1 durvalumab 1 capivasertib 1 bemarituzumab 1 abemaciclib 1 Whole-Body Irradiation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06585969 2026-02-12

DISCORDANT

Danish Breast Cancer Cooperative Group

Phase 3 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡